Contineum Therapeutics, Inc. CTNM
12.56
0.07
0.56%
as of 25 Sep
- Market cap
- $469.9M
- P/E
- 0.0×
Follow CTNM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
36.25 | 37.00 | 26.98 | 28.68 | |
Current Ratio |
37.17 | 38.00 | 27.50 | 29.07 | |
Net Debt/EBITDA |
13.68 | 14.64 | 15.44 | 12.28 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 1.13 | 0.86 | 0.95 | |
Capex/Depreciation |
(0.04) | (3.76) | (0.49) | (1.21) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.31) | (0.44) | (0.47) | (0.43) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.44) | (0.47) | (0.44) | |
Cash per Share |
6.31 | 6.60 | 9.49 | 6.49 | |
Shareholders Equity per Share |
6.40 | 6.70 | 9.42 | 6.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.40 | 6.70 | 9.42 | 6.42 | |
Free Cash Flow |
(11.51) | (16.58) | (13.08) | (12.29) | |
Working Capital |
236.05 | 246.31 | 258.17 | 178.57 | |
Capital Expenditures |
(0.01) | (0.31) | (0.04) | (0.10) | |
Net Current Asset Value |
231.87 | 241.66 | 252.26 | 174.55 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
1.25 | 2.57 | 1.41 | 1.09 | |
Average Assets |
216.63 | 229.81 | 244.74 | 203.44 | |
Average Common Equity |
205.53 | 217.40 | 229.53 | 195.35 |
Columns are period end dates